Hematology-Oncology Fellow
Icahn School of Medicine at Mount Sinai
Dr. Siegel received her MD at University of Maryland School of Medicine in 2019. She then completed her residency in internal medicine at New York University in 2022. She worked as a Hospitalist Scholar at New York University School of Medicine from 2022 to 2023. She is currently a fellow in hematology and medical oncology at the Icahn School of Medicine at Mount Sinai. While at University of Maryland School of Medicine, she received the Milford M. Foxwell, Jr., MD Award of Internal Medicine. During her training, her research insterests have been primarily focused in hematology and oncology. She worked in the lab of Dr. Benjamin Tycko at Columbia Unviersity Institute for Cancer Genetics, exploring the impact of demethylating agents on immune effector and antigen presenting cells in pancreatic ductal adenocarcinoma. Under Dr. Curt Civin, at the University of Maryland School of Medicine, she examined the role of RAB5 in erythropoiesis, for which she received the ASH HONORS Award. Under Dr. Michael McCurdy, she analyzed bleeding risk in thrombocytopenic patients receiving PICC lines, implementing changes in vascular access policy at University of Maryland Medical Center. While at NYU, she worked in the lab of Dr. Faith Davies to analyze the different clinical and cytogenetic variables in newly diagnosed multiple myeloma to better determine high risk disease, for which she received the ASH Abstract Achievement Award. She is currently working with Dr. Samir Parekh, at Mount Sinai, to better elucidate the downstream infectious impacts of biscpecific antibody therapy in multiple myeloma.